Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) FCF Margin (2016 - 2025)

Historic FCF Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 258.61%.

  • CytomX Therapeutics' FCF Margin fell 1965500.0% to 258.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.67%, marking a year-over-year increase of 64500.0%. This contributed to the annual value of 62.66% for FY2024, which is 64700.0% down from last year.
  • CytomX Therapeutics' FCF Margin amounted to 258.61% in Q3 2025, which was down 1965500.0% from 84.57% recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' FCF Margin ranged from a high of 39.58% in Q1 2023 and a low of 465.14% during Q1 2022
  • For the 5-year period, CytomX Therapeutics' FCF Margin averaged around 169.22%, with its median value being 84.57% (2025).
  • As far as peak fluctuations go, CytomX Therapeutics' FCF Margin tumbled by -17109300bps in 2021, and later soared by 5047200bps in 2023.
  • CytomX Therapeutics' FCF Margin (Quarter) stood at 282.4% in 2021, then soared by 97bps to 7.83% in 2022, then plummeted by -967bps to 83.55% in 2023, then soared by 37bps to 52.47% in 2024, then plummeted by -393bps to 258.61% in 2025.
  • Its FCF Margin was 258.61% in Q3 2025, compared to 84.57% in Q2 2025 and 41.56% in Q1 2025.